# EXtending the tIme Window of Thrombolysis by ButyphThalide up to 6 Hours After Onset (EXIT-BT)

Study · id `cardio:ct-nct05189509` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05189509](<https://clinicaltrials.gov/study/NCT05189509>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05189509

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT05189509. Randomized; single masking; primary purpose treatment. Start 2022-02-11 (actual); primary completion 2022-09-30 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT05189509, source copy `cardio:ctgov-nct05189509-2023-01-13`, retrieved 2026-10-26)
- Started: 2022-02-11 (actual) (ClinicalTrials.gov record NCT05189509, source copy `cardio:ctgov-nct05189509-2023-01-13`, retrieved 2026-10-26)
- Primary completion: 2022-09-30 (actual) (ClinicalTrials.gov record NCT05189509, source copy `cardio:ctgov-nct05189509-2023-01-13`, retrieved 2026-10-26)
- Completion: 2022-12-28 (actual) (ClinicalTrials.gov record NCT05189509, source copy `cardio:ctgov-nct05189509-2023-01-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05189509, source copy `cardio:ctgov-nct05189509-2023-01-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05189509-2023-01-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: EXtending the tIme Window of Thrombolysis by ButyphThalide up to 6 Hours After Onset (EXIT-BT)
- Condition: Stroke, Ischemic
- Intervention (Drug): TNK-Tissue Plasminogen Activator
- Lead sponsor: General Hospital of Shenyang Military Region
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as the lead sponsor: General Hospital of Shenyang Military Region (`cardio:org-general-hospital-of-shenyang-military-region`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Tenecteplase Plus Butyphthalide for Stroke Within 4.5-6 Hours of Onset (EXIT-BT): a Phase 2 Study (`cardio:pubmed-38238620`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 0d753995d11cf9a07726e7a34dacc59060c7ffc183f42f22834da0de1417fc92
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
